Global risk of cardiovascular disease
- PMID: 12695425
- PMCID: PMC1876298
- DOI: 10.1136/heart.89.suppl_2.ii2
Global risk of cardiovascular disease
Abstract
UK death rates from coronary heart disease are among the highest in the world. This is because the UK has high levels of standard risk factors and a low level of intervention on those risk factors. The most important modifiable cardiovascular risk factors are dyslipidaemia (particularly high LDL cholesterol and low HDL cholesterol), smoking, hypertension, glucose intolerance, and central obesity. Intervention strategies that do not target those individuals at highest cardiovascular risk are likely to be less cost effective. Global risk estimation is increasingly recognised by management guidelines as a clinically and cost effective means of guiding treatment. However, an over reliance on short term absolute risk may result in under treatment of young people (particularly women) at high relative risk and over treatment of older people (particularly men) at low relative risk.
Figures
Similar articles
-
[The role of lipid metabolism in the prevention of coronary heart disease].Z Kardiol. 2005;94 Suppl 3:III/43-55. doi: 10.1007/s00392-005-1307-x. Z Kardiol. 2005. PMID: 16258792 German.
-
[Statins in primary prevention of coronary heart disease].Wien Med Wochenschr. 1999;149(5-6):129-38. Wien Med Wochenschr. 1999. PMID: 10408004 Review. German.
-
Plasma triglyceride level and mortality from coronary heart disease.N Engl J Med. 1993 Apr 29;328(17):1220-5. doi: 10.1056/NEJM199304293281702. N Engl J Med. 1993. PMID: 8464432
-
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003. Drugs. 2004. PMID: 15161326 Review.
-
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.Curr Med Res Opin. 2004 Sep;20(9):1385-92. doi: 10.1185/030079904125004484. Curr Med Res Opin. 2004. PMID: 15383187 Clinical Trial.
Cited by
-
Turbina oblongata Protects Against Oxidative Cardiotoxicity by Suppressing Lipid Dysmetabolism and Modulating Cardiometabolic Activities Linked to Cardiac Dysfunctions.Front Pharmacol. 2021 May 20;12:610835. doi: 10.3389/fphar.2021.610835. eCollection 2021. Front Pharmacol. 2021. PMID: 34093172 Free PMC article.
-
Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.Br J Clin Pharmacol. 2008 May;65(5):775-86. doi: 10.1111/j.1365-2125.2007.03072.x. Epub 2008 Feb 14. Br J Clin Pharmacol. 2008. PMID: 18279464 Free PMC article.
-
Alpha-Adrenergic Mechanisms in the Cardiovascular Hyperreactivity to Norepinephrine-Infusion in Essential Hypertension.Front Endocrinol (Lausanne). 2022 Jul 22;13:824616. doi: 10.3389/fendo.2022.824616. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35937820 Free PMC article.
-
Blood pressure in adult rural INDEPTH population in Asia.Glob Health Action. 2009 Sep 28;2. doi: 10.3402/gha.v2i0.2010. Glob Health Action. 2009. PMID: 20027254 Free PMC article.
-
The Role of Chemokines and Small Leucine-Rich Proteoglycans in Cardiac Remodeling in Immunosuppressant-Treated Male Rats.Int J Mol Sci. 2025 Jul 3;26(13):6414. doi: 10.3390/ijms26136414. Int J Mol Sci. 2025. PMID: 40650190 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources